Effect of Chemical Enhancers in Transdermal Permeation of Alfuzosin Hydrochloride. (20th December 2012)

• Record Type: Journal Article
• Authors: Prasanthi, D.; Lakshmi, P. K.
• Other Names: Arima H. Academic Editor.; Saturnino C. Academic Editor.
• Is Part Of: ISRN pharmaceutics. Volume 2012(2012)
• Publication Date: 2012-12-20
• Subjects: Pharmacy -- Periodicals; Pharmacological Phenomena; Pharmacology; Pharmacy; Electronic journals; Periodical; Periodicals; 615
• DOI: 10.5402/2012/965280
• Languages: English
• ISSNs: 2090-6145

Abstract

Abstract : The objective of the present study is to explore the efficient chemical penetration enhancer among the various enhancers available in overcoming the stratum corneum barrier in transdermal delivery of Alfuzosin hydrochloride (AH). The different enhancers were incorporated in 2% Carbopol gel which was selected as a control and evaluated by in vitro diffusion studies through dialysis membrane and permeation through the rat abdominal skin using Keshary-Chien diffusion cells. All the enhancers increased the release rate through the dialysis membrane when compared with control except oleic acid which decreased the release rate but showed maximum solubility of the drug. Among the various enhancers Transcutol 20% and tween-20 (2%) showed the highest cumulative amount ( Q 24 ) of 702.28 ± 6.97 μ g/cm 2 and 702.74 ± 7.49 μ g/cm 2, respectively. A flux rate of 31.08 ± 0.21 μ g/cm 2 /hr by Transcutol 20% and 30.38 ± 0.18 μ g/cm 2 /hr by tween-20 (2%) was obtained. Transcutol 20% showed decreased lag time of 0.13 ± 0.05 hr. The lowest skin content of 342.33 ± 5.30 μ g/gm was seen with oleic acid 2.5%. Maximum enhancement of flux by 3.94-fold was obtained with transcutol 20%. Primary skin irritation studies were performed with rabbit. Histopathological studies of transcutol 20% showed marked changes such as degeneration and infiltration of mononuclear cells in dermis indicating the effect of transcutol on the skin. Among the different enhancers transcutol is efficient in enhancing transdermal delivery of AH.